Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.52 |
| ▸ | LOX | P28300 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.44 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29623349 | 1.00 | LOXL2 (0.52) | LOXL2LOXIDO1SMARCA2SMARCA4 | |
| SCHEMBL1274457 | 0.84 | IDH1 (0.40) | LOXL2LOXIDO1 | |
| SCHEMBL23181537 | 0.83 | IDH1 (0.39) | LOXL2LOXIDO1SMARCA2SMARCA4 | |
| SCHEMBL17562223 | 0.77 | PRKCI (0.41) | LOXL2HDAC4HDAC8 | |
| SCHEMBL23639222 | 0.77 | SMARCA2 (0.51) | LOXL2LOXIDO1SMARCA2SMARCA4 | |
| SCHEMBL30328281 | 0.74 | LOXL2 (0.53) | LOXL2LOXIDO1SMARCA2SMARCA4 | |
| SCHEMBL2327508 | 0.74 | NOS3 (0.59) | LOXL2LOXIDO1SMARCA2SMARCA4 | |
| SCHEMBL1643559 | 0.74 | LOXL2 (0.53) | LOXL2LOXIDO1SMARCA2SMARCA4 | |
| SCHEMBL2642373 | 0.74 | LOXL2 (0.53) | LOXL2LOXIDO1SMARCA2SMARCA4 | |
| SCHEMBL23180951 | 0.74 | TGFBR1 (0.37) | HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630533-B2 | Heterocyclic compounds useful as KCNT1 inhibitors | ACTIO BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| US-20250313548-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS | ACTIO BIOSCIENCES, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| US-20250100996-A1 | HETEROCYCLOALKYL AND HETEROARYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT MODULATE IKZF2 | Plexium, Inc. | 2025-03-27 | — | — | US | disclosed |
| US-12202826-B2 | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | REDX PHARMA PLC (GB) | 2025-01-21 | — | — | US | disclosed |
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4436976-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-4366835-A1 | HETEROCYCLOALKYL AND HETEROARYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT MODULATE IKZF2 | Plexium, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11883387-B2 | PqsR inverse agonists | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2024-01-30 | — | — | US | disclosed |
| EP-1802307-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-07-04 | — | — | EP | disclosed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1270582-B1 | TRIPHENYLPHOSPHINE DERIVATIVES, PALLADIUM OR NICKEL COMPLEXES THEREOF, AND PROCESS FOR PREPARING BIARYL DERIVATIVES | MITSUBISHI RAYON CO (JP) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006040192-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-04-20 | — | — | WO | disclosed |
| EP-1615909-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004101546-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| US-6693210-B2 | USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS | MITSUBISHI RAYON CO., LTD. (JP) | 2004-02-17 | — | — | US | disclosed |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | MITSUBISHI RAYON CO., LTD. (JP) | 2003-04-03 | — | — | US | disclosed |
| EP-1270582-A1 | TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE | Mitsubishi Rayon Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100996-A1 | HETEROCYCLOALKYL AND HETEROARYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT MODULATE IKZF2 | IKZF1, CRBN, IKZF3 | LOXL2 1538/4885LOX 2722/4885IDO1 527/4885 |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GRIN2A, GRIK5, GRIN2C | LOXL2 3009/4885LOX 2138/4885IDO1 1688/4885 |
| US-12202826-B2 | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | WNT1, WNT3, CTNNB1 | LOXL2 2604/4885LOX 3640/4885IDO1 958/4885 |
| US-20250313548-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS | KCNT1, KCNT2, KCNN3 | LOXL2 3755/4885LOX 3319/4885IDO1 4424/4885 |
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, NR1H2, PMP22 | LOXL2 2742/4885LOX 3044/4885IDO1 4770/4885 |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | PDCD1LG2, PIK3CA, PDCD1 | LOXL2 3892/4885LOX 4221/4885IDO1 1439/4885 |
| US-12630533-B2 | Heterocyclic compounds useful as KCNT1 inhibitors | KCNT1, KCNT2, KCNJ2 | LOXL2 2853/4885LOX 2507/4885IDO1 1863/4885 |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | LOXL2 762/4885LOX 846/4885IDO1 2064/4885 |
| US-11883387-B2 | PqsR inverse agonists | QRFPR, P2RY11, QARS1 | LOXL2 4197/4885LOX 4457/4885IDO1 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.